Federal Study Finds No Benefit of New Antipsychotic Drugs – WashPost/Wall StreetJ/NY Times Tue, 20 Sep 2005 The findings of a $44 million government sponsored study, CATIE, published in The New England Journal of Medicine, comparing an older generic antipsychotic to four new atypical antipsychotics, undercut the legitimacy of psychiatry’s…
Lilly to Add Suicide Warning to Strattera – Medicaid May shrink $5.5 Billion spending on Schizophrenia Drug Thu, 29 Sep 2005 Reuters reports that Eli Lilly is adding a Black Box suicide warning to the Strattera label. Strattera has been promoted as a “non stimulant” treatment for ADHD. Since ADHD…
Merck / Johnson & Johnson/ Lilly-Zyprexa: $690 Million settlement / a Flowering of Diabetes Drugs Fri, 10 Jun 2005 A cluster of news reports about three pillars of the pharmaceutical industry– Merck, Eli Lilly, and Johnson & Johnson–leave no doubt that this industry has shown its disregard for the welfare…
"The drugs most commonly used to soothe agitation and aggression in people with Alzheimer’s disease are no more effective than placebos for most patients, and put them at risk of serious side effects, including confusion, sleepiness and Parkinson’s disease-like symptoms, researchers are reporting
today."
“a study published yesterday overturns conventional wisdom about antipsychotic drugs, which cost the United States $10 billion a year.”
USA Today reports that last year the pharmaceutical industry "faced the most product liability lawsuits of any other industry."
Industry’s blockbuster sellers–the atypical antipsychotics performed WORSE than their cheaper, non-patented precursors.
A front page report in The New York Times describes a psychotropic drug-induced catastrophe that has befallen patients who obeyed their
psychiatrists, and swallowed the antipsychotic drugs prescribed by psychiatrists who insisted the drugs were for the patients own good.
"I trusted the doctors, I trusted the FDA … and I feel betrayed by both," says Erin Evans, the mother of Rex who was prescribed the ‘atypical’ antipsychotic, Risperdal (risperidone) at age 8.
"Are we becoming patients for profit? That is the question knowledgeable observers are asking.
Psychiatry’s professional practice paradigm has received a major blow.
Newly published results (phase II) from the CATIE schizophrenia treatment efficacy study sponsored by the National Institute of Mental Health comparing the most commonly used second generation drug treatments for schizophrenia and depression, is highly disturbing.
